

DAFTAR ISI

HALAMAN JUDUL	i
LEMBAR PENGESAHAN	ii
HALAMAN PENGESAHAN PANITIA PENGUJI	iii
HALAMAN PERSETUJUAN PUBLIKASI	iv
HALAMAN ORISINALITAS PENELITIAN	v
KATA PENGANTAR	vi
ABSTRAK	ix
ABSTRACT	x
DAFTAR ISI	xi
DAFTAR TABEL	xiv
DAFTAR GAMBAR	xv
DAFTAR SINGKATAN	xvi
BAB1 PENDAHULUAN	1
1.1 Latar Belakang	1
1.2 Rumusan Masalah.....	5
1.3 Tujuan Penelitian	5
1.3.1 Tujuan Umum.....	5
1.3.2 Tujuan Khusus	5
1.4 Manfaat Penelitian	6
1.4.1 Manfaat Teoritis	6
1.4.2 Manfaat Klinis	6
BAB 2 TINJAUAN PUSTAKA	7
2.1 Definisi Kanker Payudara	7
2.2 Faktor Risiko Kanker Payudara	7
2.3 Epidemiologi.....	8
2.4 <i>Locally advance Breast Cancer</i>	9
2.4.1 <i>Diagnosis Locally Advance Breat Cancer</i>	9
2.4.2 Tatalaksana Kanker Payudara Lanjut Lokal.....	11

2.5	Kemoterapi Neoadjuvan pada <i>Locally Advance Breast Cancer</i>	11
2.5.1	Regimen Kemoterapi Neoadjuvan CAF.....	13
2.6	Vitamin D pada Kanker Payudara	16
2.6.1	Fisiologi, Fungsi, dan Defisiensi Vitamin D	15
2.6.2	Metabolisme Vitamin D	18
2.6.3	Vitamin D Reseptor	20
2.6.4	Pengukuran dan Kadar Optimal Vitamin D	25
2.6.5	Faktor-faktor yang mempengaruhi vitamin D.....	26
2.7	Respon Radiologis Kemoterapi Neoadjuvan	28
2.7.1	Ultrasonografi Payudara Sebagai Monitoring Respons Neoadjuvan Terapi.....	28
BAB 3 KERANGKA KONSEPTUAL		38
3.1	Kerangka Konseptual.....	38
3.2	Penjelasan Kerangka Konseptual.....	39
3.3	Hipotesis Penelitian	40
BAB 4 METODE PENELITIAN		41
4.1	Jenis dan Rancangan Penelitian	41
4.2	Populasi Penelitian.....	41
4.3	Sampel Penelitian.....	41
4.4	Besar Sampel	41
4.4.1	Pengambilan Sampel	42
4.5	Kriteria Penelitian	42
4.5.1	Kriteria Inklusi.....	42
4.5.2	Kriteria Eksklusi	43
4.6	Variabel Penelitian	43
4.7	Definisi Operasional	43
4.8	Prosedur Penelitian	46
4.8.1	Pengumpulan Data.....	46
4.8.2	Analisis Data.....	38
4.9	Kerangka Operasional.....	48
4.10	Lokasi, Waktu dan Jadwal Penelitian.....	49

4.10.1 Lokasi Penelitian.....	49
4.10.2 Waktu Penelitian.....	49
4.11 Biaya Penelitian.....	50
BAB 5 HASIL PENELITIAN.....	51
5.1 Deskripsi Penelitian.....	51
5.2 Karakteristik Subyek Penelitian.....	51
5.3 Kadar Vitamin D Pada Pasien Locally Advance Breast Cancer.....	53
5.4 Respons Kemoterapi Pada Pasien Locally Advance Breast Cancer yang Menjalani Kemoterapi CAF.....	53
5.5 Hubungan Vitamin D dengan Respons Kemoterapi Pada Pasien Locally Advance Breast Cancer yang Menjalani Kemoterapi CAF.....	54
BAB 6 PEMBAHASAN.....	56
BAB 7 KESIMPULAN DAN SARAN.....	61
7.1 Kesimpulan.....	61
7.2 Saran.....	61
DAFTAR PUSTAKA.....	62
LAMPIRAN.....	66

DAFTAR TABEL

Tabel 2.1 Stadium Kanker Payudara Lanjut Lokal	10
Tabel 2.2 Perbandingan respon tumor padat berdasar RECIST dan WHO	32
Tabel 4.1 Tabel Kegiatan Waktu Penelitian	49
Tabel 5.1 Karakteristik Subjek Penelitian.....	52
Tabel 5.2 Kadar Vitamin D pada pasien dengan <i>locally Advance Breast Cancer</i> yang menjalani kemoterapi CAF	53
Tabel 5.3 Ukuran Pre dan Post Kemoterapi.....	54
Tabel 5.4 Kadar Vitamin D dan Respon Kemoterapi	54

DAFTAR GAMBAR

Gambar 2.1 Regulasitranskripsimelalui VDR.....	21
Gambar 2.2 Jalur pensinyalan kanker yang berkaitan dengan VDR... ..	23
Gambar 2.3 USG Payudara.....	36
Gambar 3.1 Kerangka Konseptual... ..	38
Gambar 4.1 USG pada Kanker Payudara.....	47
Gambar 4.2 Kerangka Operasional Penelitian... ..	48

DAFTAR SINGKATAN

1,25[OH]2D	<i>1,25-dihydroxyvitamin D atau Calcitriol</i>
25[OH]D	<i>25-hydroxyvitamin D atau Calcidiol</i>
AACE	<i>American Association of Clinical Endocrinologists</i>
AJCC	<i>American Joint Committee on Cancer</i>
ATM	<i>Ataxia-Teleangoectasia Mutated</i>
BAD	<i>BCL2 Antagonist of Cell Death</i>
BAK	<i>BCL2 Homologous Antagonist Killer</i>
BAX	<i>BCL2- Associated X Protein</i>
BCS	<i>Breast Conserving Surgery</i>
BC12	<i>B-cell Lymphoma 2</i>
BCI-XL	<i>B-cell Lymphoma eXtra Large</i>
BMS	<i>Bone Mineral Density</i>
BRCA1	<i>BReast CAncer susceptibility gene 1</i>
BRCA2	<i>BReast CAncer susceptibility gene 2</i>
CAF	<i>Cyclophosphamid, Adriamycin, Fluorouracil</i>
CDC	<i>Centers for Disease Control and Prevention</i>
CDK	<i>Cyclin-Dependent Kinase</i>
CKD	<i>Chronic Kidney Disease</i>
CAF	<i>Cyclophosphamide, adriamycin, Fluorouracil</i>
CBP	<i>CERB binding protein</i>
CEF	<i>Cyclophosphamide, Epirubicin, Fluorouracil</i>
CR	<i>Complete Response</i>
Cu	<i>Cuprum</i>
DBP	<i>Vitamin D Binding Protein</i>
DFS	<i>Disease Free Survival</i>
DNA	<i>Deoxyribonucleic Acid</i>
ESMO	<i>European Society for Medical Oncology</i>
HER2	<i>Human Epidermal Growth Factor Receptor 2</i>
IARC	<i>International Agency for Research on Cancer</i>
IMT	<i>Indeks Massa Tubuh</i>

LABC	<i>Locally Advanced Breast Cancer</i>
MCF7	<i>Michigan Cancer Foundation 7</i>
MMP9	<i>Matrix Metalloproteinase 9</i>
MRM	<i>Modified Radical Mastectomy</i>
MRI	<i>Magnetic Resonance Imaging</i>
NAC	<i>Neoadjuvant chemotherapy</i>
NCCN	<i>National Comprehensive Cancer Network</i>
ng/mL	nanogram per milliliter
nmol/L	nanomol per liter
OS	<i>Overall Survival</i>
P53	<i>Phosphoprotein 53</i>
pCR	<i>Partial Complete Respon</i>
PD	<i>Progressive Disease</i>
PR	<i>Partial Response</i>
PRL	<i>Prolactin</i>
PTH	<i>Parathyroid Hormone</i>
RECIST	<i>Response Evaluation Criteria in Solid Tumours</i>
RLU	<i>Relative Light Unit</i>
RNA	<i>Ribonucleic Acid</i>
RXR	<i>Retinoid Acid X Receptor</i>
SD	<i>Stable Disease</i>
SI	Sistem Internasional
SRC	<i>Steroid reseptor Coaktivator</i>
SNP	<i>Single nucleotid polymorfisme</i>
TS	<i>Thymidylate Synthetase</i>
US NIST	<i>U.S. National Institute of Standards and Technology</i>
UV	<i>Ultra Violet</i>
USG	<i>Ultrasonography</i>
VDR	<i>Vitamin D Receptor</i>
VDRE	<i>Vitamin D Response Element</i>
WHO	<i>World Health Organization</i>
Zn	<i>Zinc</i>